Colorectal Cancer Mortality Rates Increasing in Younger White Patients

Article

Mortality from colorectal cancer has decreased since 1970 in young black patients aged 20 to 54, but has increased in white patients since 1995 in those aged 30 to 39 years and since 2005 in those aged 40 to 54 years after decades of decreasing.

Mortality from colorectal cancer (CRC) has decreased since 1970 in young black patients aged 20 to 54, but has increased in white patients since 1995 in those aged 30 to 39 years and since 2005 in those aged 40 to 54 years after decades of decreasing, according to a research letter published in JAMA.

Rebecca L. Siegel, MPH, of the American Cancer Society in Atlanta, Georgia, and colleagues, wrote that these “disparate racial patterns conflict with trends in major CRC risk factors like obesity, which are similar in white and black individuals,” and that the “increased mortality is particularly unexpected among those aged 50 to 54 years, for whom screening has been recommended since the 1970s.”

The researchers obtained CRC mortality rates per 100,000 population from 1970 to 2014 from the SEER Stat database. Data obtained was for individuals aged 20 to 54 years and mortality data was from causes reported on death certificates.

From 1970 to 2014, 242,637 people died from CRC. Median age at death was 49 years. Overall, CRC mortality rates declined in those aged 20 to 54 from 6.3 per 100,000 in 1970 to 3.9 per 100,000 in 2004. However, rates then increased by 1% annually to 4.3 per 100,000 in 2014.

Data revealed that this increase in mortality occurred only in white individuals, where mortality rates increased by 1.4% annually from 3.6 per 100,000 in 2004 to 4.1 per 100,000 in 2014. Conversely, black individuals saw decreases in mortality rates from 8.1 per 100,000 in 1970 to 6.1 per 100,000 in 2014.

Throughout the entire study period, black individuals had decreasing mortality rates among those aged 20 to 49; since 1993, mortality rates also decreased among those aged 50 to 54. In contrast, mortality rates increased for white individuals aged 30 to 39 from 1995 to 2014 and for those aged 40 to 49 and 50 to 54 from 2005 to 2014.

“This study is limited by its ecologic nature and inaccuracies in about 5% of all death certificates listing CRC as the underlying cause of death,” the researchers wrote. “Escalating mortality rates in young and middle-aged adults highlight the need for earlier CRC detection through age-appropriate screening and more timely follow-up of symptoms.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content